Ojjaara
(momelotinib)
Get free couponsJakafi
(ruxolitinib)
Get free couponsSummary for Ojjaara
Ojjaara (momelotinib) is FDA approved to treat a rare type of blood cancer called myelofibrosis (MF) in adults with anemia. It works as a JAK inhibitor to help stop abnormal blood cells from growing out of control. Ojjaara (momelotinib) comes as a tablet that you take by mouth once a day. But the medication can cause side effects like bleeding, diarrhea, and tiredness. It also has a risk of infection and liver problems.
Indications for Ojjaara
- Intermediate or high-risk myelofibrosis (MF) in adults who also have anemia
Pros and Cons for Ojjaara
Pros
- A pill that’s taken once a day
- Might be specifically beneficial in people who have both myelofibrosis and anemia
Cons
- Can cause side effects such as bleeding and diarrhea
- Not recommended during pregnancy or while breastfeeding
Common Side Effects for Ojjaara
- Low platelets (28%)
- Diarrhea (22%)
- Bleeding (22%)
- Tiredness (21%)
- Nausea (16%)
- Bacterial infection (15%)
- Stomach pain (13%)
- Viral infection (12%)
- Itchiness (11%)
- Higher liver enzyme levels (10%)
- Fever (10%)
Warnings for Ojjaara
- Risk of infections
- Low platelets and low white blood cells
- Liver problems
- Severe skin reactions
- Possible serious health outcomes, like heart-related death, heart attack, and stroke
- Possible blood clots
- New cancers
- Worsening of symptoms after pausing or stopping treatment
Summary for Jakafi
Jakafi (ruxolitinib) is a JAK inhibitor that’s used to treat adults with certain blood conditions called myelofibrosis (MF) and polycythemia vera (PV). This medication is also used to treat graft-versus-host disease (GVHD) in people 12 years and older. Jakafi (ruxolitinib) is a tablet that you take by mouth twice a day. It can cause side effects like low blood cell counts, infection, and tiredness.
Indications for Jakafi
- Intermediate or high-risk myelofibrosis (MF) in adults
- Polycythemia vera (PV) in adults who can’t take or have already tried hydroxyurea (Hydrea)
- Acute graft-versus-host disease (aGVHD) in people 12 years and older who’ve already tried corticosteroids
- Chronic graft-versus-host disease (cGVHD) in people 12 years and older who’ve already tried at least one therapy option already
Pros and Cons for Jakafi
Pros
- Taken by mouth; no needles required
- Recommended treatment for myelofibrosis and polycythemia vera
- Doesn’t typically cause nausea or vomiting
- Works in a more targeted, specific way than traditional chemotherapy
Cons
- Taken twice a day and might require dose changes often
- Often causes low blood cell counts
- Might raise your risk for infection
Common Side Effects for Jakafi
- Infection (e.g., urinary tract infection, viral infection)
- Muscle, bone, or joint pain
- Anemia (low red blood cells)
- Low white blood cells
- Low platelets
- High cholesterol levels
- Higher liver enzyme levels in blood
Warnings for Jakafi
- Low blood cell counts
- Risk of infection
- Risks when Jakafi (ruxolitinib) is paused or stopped
- Skin cancer
- Possible risk for serious heart problems and stroke
- Possible risk for blood clots
- Possible risk for new cancers
Prices with our coupons for Ojjaara vs. Jakafi
Browse medications by letter
Show AllBrowse prescription and over-the-counter medications from A to Z, compare drug prices, and start saving.
